|
1
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, et al: Cancer incidence and mortality patterns
in Europe: estimates for 40 countries in 2012. Eur J Cancer.
49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneider J: Tumor markers in detection of
lung cancer. Adv Clin Chem. 42:1–41. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harmsma M, Schutte B and Ramaekers FC:
Serum markers in small cell lung cancer: opportunities for
improvement. Biochim Biophys Acta. 1836.255–272. 2013.
|
|
6
|
Chu XY, Hou XB, Song WA, Xue ZQ, Wang B
and Zhang LB: Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for
lung cancer in patients with suspicious pulmonary masses: a single
center analysis. Cancer Biol Ther. 11:995–1000. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kley K and Oehr P: Usefulness of combined
FDG-PET with CT or tumour markers in lung cancer diagnosis.
Anticancer Res. 30:1741–1745. 2010.PubMed/NCBI
|
|
8
|
Grunnet M and Sorensen JB:
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung
Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Witze ES, Old WM, Resing KA and Ahn NG:
Mapping protein post-translational modifications with mass
spectrometry. Nat Methods. 4:798–806. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhukov TA, Johanson RA, Cantor AB, Clark
RA and Tockman MS: Discovery of distinct protein profiles specific
for lung tumors and pre-malignant lung lesions by SELDI mass
spectrometry. Lung Cancer. 40:267–279. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Howard BA, Wang MZ, Campa MJ, Corro C,
Fitzgerald MC and Patz EF Jr: Identification and validation of a
potential lung cancer serum biomarker detected by matrix-assisted
laser desorption/ionization-time of flight spectra analysis.
Proteomics. 3:1720–1724. 2003. View Article : Google Scholar
|
|
12
|
Yang SY, Xiao XY, Zhang WG, et al:
Application of serum SELDI proteomic patterns in diagnosis of lung
cancer. BMC Cancer. 5:832005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Indovina P, Marcelli E, Pentimalli F,
Tanganelli P, Tarro G and Giordano A: Mass spectrometry-based
proteomics: the road to lung cancer biomarker discovery. Mass
Spectrom Rev. 32:129–142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maciel CM, Junqueira M, Paschoal ME,
Kawamura MT, Duarte RL, Carvalho Mda G and Domont GB: Differential
proteomic serum pattern of low molecular weight proteins expressed
by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 5:31–38.
2005.PubMed/NCBI
|
|
15
|
Liu L, Liu J, Dai S, et al: Reduced
transthyretin expression in sera of lung cancer. Cancer Sci.
98:1617–1624. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu L, Liu J, Wang Y, et al: A combined
biomarker pattern improves the discrimination of lung cancer.
Biomarkers. 16:20–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lim A, Sengupta S, McComb ME, Théberge R,
Wilson WG, Costello CE and Jacobsen DW: In vitro and in vivo
interactions of homocysteine with human plasma transthyretin. J
Biol Chem. 278:49707–49713. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Connors LH, Lim A, Prokaeva T, Roskens VA
and Costello CE: Tabulation of human transthyretin (TTR) variants,
2003. Amyloid. 10:160–184. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ingenbleek Y and Young VR: Significance of
transthyretin in protein metabolism. Clin Chem Lab Med.
40:1281–1291. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Potter MA and Luxton G: Transthyretin
measurement as a screening tool for protein calorie malnutrition in
emergency hospital admissions. Clin Chem Lab Med. 40:1349–1354.
2002. View Article : Google Scholar
|
|
21
|
Schweigert FJ and Sehouli J:
Transthyretin, a biomarker for nutritional status and ovarian
cancer. Cancer Res. 65:11142005.PubMed/NCBI
|
|
22
|
Buxbaum JN: The systemic amyloidoses. Curr
Opin Rheumatol. 16:67–75. 2004. View Article : Google Scholar
|
|
23
|
Buxbaum JN and Reixach N: Transthyretin:
the servant of many masters. Cell Mol Life Sci. 66:3095–3101. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kozak KR, Su F, Whitelegge JP, Faull K,
Reddy S and Farias-Eisner R: Characterization of serum biomarkers
for detection of early stage ovarian cancer. Proteomics.
5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Farias-Eisner G, Su F, Robbins T,
Kotlerman J, Reddy S and Farias-Eisner R: Validation of serum
biomarkers for detection of early- and late-stage endometrial
cancer. Am J Obstet Gynecol. 202:73.e1–73.e5. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Travis WD, Colby TV, Corrin B, et al:
Histological Typing of Lung and Pleural Tumours. 3rd edition.
Springer; Berlin: 1999, View Article : Google Scholar
|
|
27
|
Heinold A, Kuehl B, Brenner-Weiss G, Opelz
G and Tran TH: Sequential analysis by
immunoprecipitation-MALDI-TOF: a novel method for detection and
identification of alloantibody specificities. Hum Immunol.
71:462–467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grus FH, Joachim SC, Sandmann S, Thiel U,
Bruns K, Lackner KJ and Pfeiffer N: Transthyretin and complex
protein pattern in aqueous humor of patients with primary
open-angle glaucoma. Mol Vis. 14:1437–1445. 2008.PubMed/NCBI
|
|
29
|
Wang Z, Wang C, Huang X, Shen Y, Shen J
and Ying K: Differential proteome profiling of pleural effusions
from lung cancer and benign inflammatory disease patients. Biochim
Biophys Acta. 1824.692–700. 2012.PubMed/NCBI
|
